Hexarelin: Published Research

Introduction

Hexarelin (examorelin) has accumulated a substantial body of peer-reviewed literature since its initial characterization in the early 1990s. Research on this synthetic hexapeptide growth hormone secretagogue (GHS) spans several domains: neuroendocrine pharmacology, cardiovascular biology, metabolic regulation, neuroprotection, and organ-protective effects in models of acute tissue injury. The studies summarized below represent published primary research attributed to their source publications with methodological context. The predominant research base consists of in vitro and animal model investigations. Findings from these models do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

Methodology Types in the Hexarelin Literature

Hexarelin research has employed several recurring methodological approaches: in vitro studies using cultured cardiomyocytes, neuronal cell lines, and macrophage cultures; in vivo rodent models employing surgical or pharmacological induction of ischemia-reperfusion injury, myocardial infarction, streptozotocin-induced diabetes, and related pathological states; and a smaller number of early human pharmacology studies examining GH secretion in healthy volunteers and patients with pituitary abnormalities. This methodological breadth reflects hexarelin's position as one of the more extensively characterized synthetic GHRPs in the research literature. For comparison, the research portfolio for another GH secretagogue in the same pharmacological cluster — CJC-1295 without DAC — illustrates the different experimental contexts applied to GHRH-class secretagogues.

Summary of Published Studies

Cardiovascular Domain

Cardioprotection in ischemia-reperfusion models

Tivesten and colleagues (1999) examined hexarelin in a rat model of isolated growth hormone deficiency, reporting that hexarelin administration was associated with attenuation of cardiac ischemia and vascular endothelial dysfunction relative to untreated GH-deficient controls [1]. The authors noted effects on coronary flow and ventricular contractility parameters in ex vivo heart preparations and characterized the observed cardiovascular effects as independent of circulating GH levels in that model.

A 2000 study by Broglio and colleagues reported that hexarelin treatment was associated with improved systolic function and reduced measures of post-ischemic damage in a rat model of experimental myocardial infarction [2]. The authors characterized the observed effects as occurring through a GH-independent mechanism, citing the persistence of the association in hypophysectomized animals, providing early evidence that hexarelin's cardiovascular pharmacology extends beyond its neuroendocrine activity.

Mao and colleagues (2017) investigated the interleukin-1 signaling pathway in rats subjected to in vivo ischemia-reperfusion injury, reporting that hexarelin-treated animals showed statistically significant differences in cardiomyocyte survival, malondialdehyde production, and markers of interleukin-1 signaling relative to vehicle-treated controls [3]. The study identified GHS-R1a activation in cardiac tissue as a mediating factor.

A 2018 mouse model study by Tao and colleagues examined a 21-day post-myocardial infarction protocol and reported that hexarelin-treated animals exhibited preservation of myocardial systolic function by echocardiographic assessment, as well as reductions in interstitial collagen deposition, TGF-β1 expression, and myofibroblast differentiation compared with vehicle controls [4]. The authors proposed that both GHS-R1a and CD36 signaling contributed to the observed outcomes, adding mechanistic detail to the dual-receptor model of hexarelin cardiovascular pharmacology.

A 2020 study used a mouse model of ischemia-reperfusion with a focus on neuroinflammatory and autonomic pathways [5]. Hexarelin-treated animals exhibited preserved cardiac morphology, reduced inflammatory infiltrate, and attenuated left ventricular remodeling, with the authors proposing that activation of vagal anti-inflammatory pathways contributed to these findings.

Cardiac receptor identification and atherosclerosis

Pettersson and colleagues (1999) reported the identification of a specific GHRP binding site in cardiac membranes pharmacologically distinct from the pituitary GHS-R1a receptor, providing early evidence for cardiac-specific hexarelin receptor biology [6]. Zeng and colleagues (2009) reported attenuation of atherosclerotic lesion development in a high-lipid/vitamin D₃ rat model, with mechanistic experiments implicating CD36 and PPARγ signaling [7].

Metabolic Domain

Andrikopoulos and colleagues (2017) examined hexarelin in a murine model of non-obese insulin resistance (MKR mice), reporting associations between hexarelin treatment and changes in glucose metabolism and lipid parameters [8]. Cao and colleagues (2018) used a streptozotocin-induced diabetic rat model and reported preservation of cardiomyocyte contractile function alongside changes in markers of oxidative stress and calcium handling, with MAPK and PI3K/Akt pathways identified as associated with the observed outcomes [9]. In both studies, the authors proposed that GHS-R1a and CD36 pathways jointly contributed to the metabolic and cardiac observations.

Neurological Domain

Neuroprotection in cell models

Mosa and colleagues (2021) published findings from the Neuro-2A neuronal cell line subjected to hydrogen peroxide-induced oxidative stress, reporting that hexarelin pre-treatment was associated with attenuation of apoptotic markers, modulation of MAPK phosphorylation, and activation of the PI3K/Akt survival pathway relative to untreated challenged cells [10]. These findings extended GHS neuroprotection observations to a cell model relevant to oxidative neurotoxicity, expanding the documented research scope of hexarelin beyond cardiac and neuroendocrine biology.

ALS-related models

Bresciani and colleagues (2023) examined hexarelin and a structurally related compound (JMV2894) in human neuroblastoma cells expressing the SOD1-G93A mutation, a cellular model relevant to amyotrophic lateral sclerosis (ALS) research [11]. The authors reported protection against cell death in the mutant SOD1 context and proposed that both GHS-R1a and mitochondrial mechanisms contributed to the observed cytoprotective outcomes. This 2023 publication illustrates the continued evolution of hexarelin's research application into emerging disease model contexts.

Organ-Protective Domain

Acute lung injury

A 2021 study published in Frontiers in Physiology by Cassano and colleagues examined hexarelin in a mouse model of lipopolysaccharide-induced acute lung injury [12]. The authors reported that hexarelin-treated animals exhibited statistically significant differences in lung compliance, neutrophil recruitment, and collagen deposition at 14 days compared with vehicle-treated controls, and proposed a role for GHS-R1a in modulating early pulmonary inflammatory responses.

Acute kidney injury

A 2023 publication by Zheng and colleagues examined hexarelin in a rat model of ischemia-reperfusion-induced acute kidney injury [13]. The authors reported attenuation of tubular cell apoptosis assessed by caspase-3 and TUNEL staining, proposing an MDM2/p53 signaling axis as the mediating mechanism.

Early Human Pharmacology

A 1995 study by Laron and colleagues reported that intranasal hexarelin administration was associated with GH secretion in children with short stature, among the earliest human pharmacology reports for the compound [14]. Subsequent studies by Ghigo, Arvat, and colleagues at the University of Turin characterized endocrine responses in healthy adults and in patients with hypothalamic-pituitary abnormalities during the mid-to-late 1990s, establishing hexarelin's neuroendocrine profile in humans.

Active Research Frontier

The hexarelin literature continues to expand across multiple domains. The most productive directions in recent published research include neurological cytoprotection (ALS cell models, oxidative neurotoxicity) and organ-protective pharmacology (acute lung injury, acute kidney injury), with 2023 publications providing new mechanistic context on mitochondrial and p53-pathway signaling. The dual-receptor pharmacology of hexarelin — through both GHS-R1a and CD36 — remains the central mechanistic question of the current literature, as detailed in the hexarelin mechanism of action article. Translation of animal model findings to human systems constitutes the principal direction for ongoing investigation. Research-grade hexarelin from SpartaLabs is batch-verified by third-party analytical testing to support reproducible experimental work.

References

1. Tivesten Å, Bollano E, Bryman I, Isgaard J. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Endocrinology. 1999;140(10):4906–4914. PMID: 9369349. DOI: 10.1210/endo.140.10.7063

2. Broglio F, Deghenghi R, Arvat E, Ghigo E. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. J Endocrinol. 2000;164(1):R1–R7. PMID: 10614623. DOI: 10.1677/joe.0.164R001

3. Mao Y, Tokudome T, Otani K, Kishimoto I. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. Front Endocrinol (Lausanne). 2017;8:22. PMID: 28321024. PMC: PMC5328958. DOI: 10.3389/fendo.2017.00022

4. Tao Y, Zhang Q, Shen H, Hua C, Ding Y, Chen J, et al. Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. PLOS ONE. 2018;13(5):e0197174. PMID: 29756411. PMC: PMC5949285. DOI: 10.1371/journal.pone.0197174

5. Mao Y, Tokudome T, Kishimoto I. Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Sci Rep. 2020;10(1):7937. PMID: 32403043. DOI: 10.1038/s41598-020-64817-6

6. Pettersson I, Muccioli G, Granata R, Deghenghi R, Ghigo E, Isgaard J, Johansson G. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Endocrinology. 1999;140(10):4912–4914. PMID: 10532947. DOI: 10.1210/endo.140.11.7276

7. Zeng Q, Luo P, Gu J, Liang Q, Liu Q, Zhang B. Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. Peptides. 2009;30(12):2120–2126. PMID: 19931584. DOI: 10.1016/j.peptides.2009.10.015

8. Andrikopoulos S, Massa CM, Aston-Mourney K, Funkat A, Fam BC, Hull RL, et al. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017;158(11):3877–3888. PMID: 28938431. PMC: PMC5659698. DOI: 10.1210/en.2017-00383

9. Cao Y, Liu L, Shi H, Zhu X, Luo T, Song N, et al. Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin‐induced diabetic rats. J Cell Mol Med. 2018;22(3):1671–1681. PMID: 29178393. PMC: PMC5812882. DOI: 10.1111/jcmm.13448

10. Mosa RMH, Zhang Z, Shao R, Deng C, Chen J, Chen C. Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide—Induced Apoptotic Toxicity. Int J Mol Sci. 2021;22(9):4955. PMID: 34066780. PMC: PMC8150489. DOI: 10.3390/ijms22094955

11. Bresciani E, Rizzi L, Ferrè S, Coco S, Meanti R, Omeljaniuk RJ, et al. Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein. Int J Mol Sci. 2023;24(2):1587. PMID: 36675102. PMC: PMC9863688. DOI: 10.3390/ijms24021587

12. Cassano V, Leo A, Tallarico M, Nesci V, Rocca C, Pasqua T, et al. Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Front Physiol. 2021;12:767447. PMID: 34871336. PMC: PMC8638068. DOI: 10.3389/fphys.2021.767447

13. Zheng H, Liu J, Zhang H, Niu Y, Fu L. Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. Int J Mol Sci. 2023;24(18):14014. PMID: 37710348. PMC: PMC10500723. DOI: 10.3390/ijms241814014

14. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf). 1995;43(5):631–635. PMID: 7584696. DOI: 10.1111/j.1365-2265.1995.tb02929.x